September,4-2018- PPCB is headed back to $0.77
Propanc Biopharma Inc (PPCB) stock has bounced back to life on news the company has entered a national phase on two key patents for cancer treatment.
Investor confidence in the stock has ticked higher on the strides the company has made on the development of the two key patents targeting cancer treatments. The stock is currently trading in a steep uptrend at the back of high turnover in traded shares.
Price action points to further movements on the upside as the upward momentum continues to gather pace, the stock should be on its way back to this year’s highs of $0.77 a share.
Recent Developments
Entering a national phase on two essential patents is the latest catalyst pushing the stock up the charts. The first patent details a method of eradicating cancer stem cells while the second cancer patent covers compositions for the treatment of solid tumors.
The biopharmaceutical company has filed a patent application for the two methods in major global jurisdictions and indication of how confident it remains about the new systems being a game changer in the medical world.
The patent applications will cover the company’s lead product candidate PRP, currently being used in cancer stem cell therapy.
“We have been working with PRP and cancer stem cells for several years, and our pre-clinical studies demonstrate that PRP appears to have a significant effect on killing these cells off, which are the main drivers of cancers. This is highly important because killing cancer stem cells reduces the risk of tumor recurrence, clinically,” said Dr. Julian Kenyon, Propanc BioPharma Chief Scientific Officer.
The patent filing comes months after the clinical stage company held a scientific advice meeting with the Medicines and Healthcare Products Regulatory Agency MHRA in the U.K. Discussions in the meeting centered on the investigational medicinal product program for PRP marking an essential step as the company continues to push for support and approval for the first CTA in the U.K.
Buoyed by achievements on the clinical development front the company has engaged the service of financial advisors as it looks to restructure and strengthen its balance sheet. The restructuring drive should allow the company to strengthen its balance sheet as it looks to advance PRP into the first-in-human study.
Propanc has already received an invite to make a presentation at the 25th Annual Newsmakers in the Biotech Industry. The conference is to be held on Friday, September 7th, 2018. The invitation to the conference presents a unique opportunity for the for the company to convey its story and products to an audience of international investors
“Our focus will be to present the recent advancements of our lead product candidate, PRP, and its effects against cancer stem cells as a way to control metastasis, which is the main cause of patient death from cancer,” said James Nathanielsz, Propanc Biopharma’s Chief Executive Officer.
